Heterocyclic Compounds, 3-Ring
"Heterocyclic Compounds, 3-Ring" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of organic compounds containing three ring structures, one of which is made up of more than one kind of atom, usually carbon plus another atom. The heterocycle may be either aromatic or nonaromatic
Concept/Terms
Heterocyclic Compounds, 3-Ring- Heterocyclic Compounds, 3-Ring
- 3-Ring Heterocyclic Compounds
- Compounds, 3-Ring Heterocyclic
- Heterocyclic Compounds, 3 Ring
- Heterocyclic Cpds, 3 Ring
Below are MeSH descriptors whose meaning is more general than "Heterocyclic Compounds, 3-Ring".
Below are MeSH descriptors whose meaning is more specific than "Heterocyclic Compounds, 3-Ring".
This graph shows the total number of publications written about "Heterocyclic Compounds, 3-Ring" by people in Harvard Catalyst Profiles by year, and whether "Heterocyclic Compounds, 3-Ring" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 1 | 3 |
| 2009 | 0 | 1 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 2 | 2 | 4 |
| 2013 | 1 | 1 | 2 |
| 2014 | 4 | 5 | 9 |
| 2015 | 1 | 3 | 4 |
| 2016 | 2 | 3 | 5 |
| 2017 | 4 | 6 | 10 |
| 2018 | 13 | 4 | 17 |
| 2019 | 7 | 5 | 12 |
| 2020 | 8 | 3 | 11 |
| 2021 | 4 | 10 | 14 |
| 2022 | 0 | 1 | 1 |
Below are the most recent publications written about "Heterocyclic Compounds, 3-Ring" by people in Profiles.
-
Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure. J Acquir Immune Defic Syndr. 2022 05 01; 90(1):27-32.
-
Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era. AIDS. 2021 12 15; 35(Suppl 2):S127-S135.
-
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open. 2021 10; 7(3).
-
Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey. J Antimicrob Chemother. 2021 08 12; 76(9):2400-2406.
-
Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2021 07 15; 73(2):e485-e493.
-
Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United States. AIDS Res Hum Retroviruses. 2021 11; 37(11):852-861.
-
SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung. Nat Commun. 2021 06 11; 12(1):3587.
-
Treatment of Severe Multicentric Reticulohistiocytosis With Upadacitinib. JAMA Dermatol. 2021 06 01; 157(6):735-737.
-
Gestational diabetes in women living with HIV in Botswana: lower rates with dolutegravir- than with efavirenz-based antiretroviral therapy. HIV Med. 2021 09; 22(8):715-722.
-
Weight gain and aging in people with HIV. AIDS. 2021 05 01; 35(6):987-989.